Aurobindo Pharma receives USFDA nod for generic Tofacitinib tablets

Approval for generic version of Xeljanz enables immediate launch and strengthens Aurobindo’s U.S. portfolio with its 586th ANDA approval

Aurobindo Pharma launches TheraNym, India’s largest biologics CMO

MSD joins as anchor customer as Aurobindo strengthens its position in the fast-growing global biologics manufacturing market

Aurobindo Pharma Q4 FY26 revenue rises 5.6% to Rs. 8,853 crore

Net profit stood at Rs. 921 crore for the quarter, while Europe revenues surged 30.2% YoY to Rs. 2,795 crore

Aurobindo Pharma wins key FDA nod for $138M US cough drug market entry

The drug is designed to provide temporary relief from cough caused by throat and bronchial irritation

APL Healthcare’s Unit-IV classified as VAI by the USFDA

This inspection is now closed

Eugia Pharma receives USFDA Approval for Everolimus tablets

Aurobindo Pharma Q1 FY26 PAT slips 10% YoY to Rs. 824 Cr

Aurobindo Pharma’s US formulations revenue slipped 1.9% on a year-on-year basis to Rs. 3,488 crore

CuraTeQ Biologics receives positive opinion for biosimilar Dazublys from EMA

Trastuzumab specifically binds and inhibits the human epidermal growth factor receptor 2 (HER2) protein

Eugia Pharma receives USFDA approval for Dasatinib Tablets

Dasatinib Tablets is indicated for the treatment of (i) newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia

Auro Vaccines terminates license agreement with Hilleman Laboratories Singapore

This termination of Agreement will not have any significant impact on the company and/or its subsidiaries or its financials